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of 48% grade II-IV AGVHD (N=12), none (16 Fos/Gan and 9 
LDBP) developed systemic CMV infection. No pts developed pri 
real T or secondary graft failure or grade III/IV hematological toxi- 
city 2 ° to Gan. SeveraI pts. developed transient nephrotoxicity and 
electrolyte imbalances, however all patients were on at least two 
other nephrotoxins: lipo amphotericin B (n=16), tacro/cyclo 
(u=14/2), anainoglycosides (n=4), vancomycin (n=10). No pt. 
developed permanent renal dysfunction, however dose reductions 
of Fos/Gan occurred in 7~% of pts. The probability of l-yr OS 
was 72%. In conclusion, CMV prophyla~s in AlloSCT recipients 
with LDPB in (-)R (-)D and Gan/Fos appears to be tolerable and 
100% effective in preventing CMV disease. This approach 
appears to reduce hematological toxicity of previously reported 
daiIy prophylactic Gan, but may be associated with Fos-induced 
transient nephrotoxicity, especially in combination with other 
nephrotoxic agents. 
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DIGENE HYBRID CAPTURE (DHC) CMV DNA ASSAY COMPARED TO 
CMV CULTURE AND INCIDENCE OF CMV DISEASE IN ALLOGENEIC 
HEMATOPOIETIC STEM CELL TRANSPLANTION (ASCT) 
Trevi'no, A?; Shaagh~ze~s),, P J; Hztdak, p.44 Lmzzk/'oi~, S.;; Bacbie'r, 
C ~; Le3/Iaistve, C.FJ 1. Texas 7qra,zsphz~t I zstit~te, Sar~ A~toMo, TX," 
2. ghffve'rsity of Texas Health Scie~ee Ce~ter at &m A~to~io, Sm~ 
Auto,do, Tk," 3. Joh,s Hopki~zs U~zive~'sit~, Balti~o~'e, MD; 4. &e~th- 
west Texas Methodist Hoapital, Sm~ A~ztonio, TX. 
CMV disease in CMV sero-positive patients post ASCT ranges 
from 21-43% and can be a significant cause of morbidity and mor- 
tality in this patient popuIation. The DHC CMV DNA assay uses 
CMV RNA probes which hybridize with the patient CMV DNA 
and when these hybrids are exposed to alkaline phosphatase they 
can be detected by chemiluminescence. The DHC assay is easy to 
perform and results are rapidly available in 24 to 48 hours. We 
retrospectively reviewed 104 ASCT patients transplanted between 
January 1998 and September 2002. Patients were screened weekly 
for the detection of CMV in blood, urine, and throat by culture 
and shell spin. The DHC CMV assay was also done weekly on 
blood samples fi'om all patients and a value of 2.1 pcg/ml was con- 
sidered positive. CMV disease was defined as evidence of tissue 
invasive disease. Thirteen of the 104 patients had positive CMV 
culture or shell spin results while 46 patients had positive DHC 
assay results. Twelve of the 13 patients with positive culture or 
shell spin results also had positive DHC assay results. One patient 
had a negative DHC assay but a positive urine shell spin. Only 
one patient had docmnented CMV disease with viral inclusions 
consistent with CMV found in the lung on autopsy. This patient 
had negative cultures, shell spin, and DHC CMV assay results and 
was on empiric gancyclovir prior to their death. The sensitivity 
and specificity of the DHC assay compared to CMV culture or 
shell spin was 92% and 63% respectively. In conclusion, the DHC 
assay is a sensitive test for detecting CMV and alIows }br the rapid 
institution of pre-emptive therapy that has resulted in a low insti- 
tutionai incidence of CMV disease. 
pos~t,,ie DF ~pOsitive cultulti,!~ s l!l,vphll negative cu]ti! or shell spin 
chemotherapy. Current data, however, does not specifically 
address whether the use ofrHu Epo in autologous stem cell trans- 
plant patients ignificantly reduces the number of RBC transfu- 
sions, leading to improved quality of life. Retrospectively, we eval- 
uated RBC transfusion usage in similar patient cohorts before and 
after the introduction of rHu-Epo in a single institutional setting. 
Data were reviewed from 111 nol~- rHu-Epo treated and 58 rHu- 
Epo treated adult non-leukemic autologous tem cell transplant 
patients drawn from a 5-year period. Beginning March 2002, a 
uniform institutional protocol for rHu-Epo usage was established 
(40, 000 units sq qweek through day +40 or upon achieving asus- 
tained HCT level of 35%). All patients received similar dosages of 
GNI-CSF post transplant (300mcg/day +4 through ANC recovery 
of 1.5). All patients had similar disease types, identical mobiliza- 
tion protocols (using G-CSF alone), similar infused CD34+ 
counts and followed identical protocol guidelines for RBC trans 
fusions. The rHu-Epo treated cohort resulted in an average of 3.2 
units of RBCs transfused through day +28 as compared to 3.8 
units in the non- rHu-Epo treated group (p=.07). In conclusion, 
tim data suggests that the use of rHu-Epo in autologous stem cell 
transplant patients may reduce the need for RBC transfusions by 
15%. Future studies using various sequencing or dosing of ery- 
thropoetin may provide a greater eduction in RBC usage in 
autologous stem cell transplant patients. 
256 
UTILIZING A CUSTOMIZED EPIDEMIOLOGICAL, DRUG-SUSCEPTIBILI- 
TY DATABASE TO MONITOR RESISTANCE PATTERNS AND TRENDS 
TO MAKE APPROPRIATE EMPIRIC ANTIBIOTIC SELECTIONS FOR 
BLOOD AND MARROW TRANSPLANT RECIPIENTS 
I, Uhite, 3/i.J; MnmlomTe, K.:; Saracino, G.~-; ShaJ~z/ol~, R.1; Agm'a, 
E. D. l; BeIv'ylllall, R. I; Ph~ei,v, L. 1; Fay, 7 W. l; 3/lmzth L. e; k~*we, E. l 
l. Baylov-SmmHolzs Gt~zcer CeJztel, Texas O*~eology, P.A,, Dallas, TX; 
2. B~O&r UniveTsi{y 3/ledkrd CenteJ, Dallas, T)L 
We followed all blood and marrow transplant patients over a 2 
year period, monitoring epidemiological trends and drug suscepti- 
bility information to choose the most appropriate mpiric antibi- 
otic selection for our febrile, neutropenic patients. The most com- 
monly seen bacterial bloodstream organisms isolated during this 
time period were coagulase n gative staphylococcus (n=323), 
Enterococcus species (n=54) and Pseudomonas species (n=42). 
Each time a gram-negative organism was isolated, it was tested 
against he institutions standardized drug susceptibility panels. Of 
all the gram negative isolates tested, Piperacillin/Tazobactam 
(pip/tazo) performed the best in our patient population, being 
reported as susceptible 107 times it was tested, resistant 41 times, 
and intermediate 5 times. The next 2 antibiotics with the highest 
susceptibilities were ceftazidilne and cefepime. When monitoring 
Pseudomonas resistance patterns over the 2 year period, the least 
resistance was seen with pip/tazo and cefepime, with an average 
resistance of approximately 30 percent. The lowest sensitivities 
were observed with imipenem and the quinolones. Based on the 
data gathered in this database, the use of pip/tazo appears to be 
the most appropriate beta-lactam selection for our patient popula- 
tion for empiric management of febrile neutropenia. In addition 
to providing coverage against most strains of Pseudomonas seen in 
our population, it also offers the advantage of providing some 
enterococcal coverage, which was also observed to be one of our 
most predominant organisms. Such a database allows for a 
prospective means of developing rotational antibiotic selections. 
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EFFECTIVENESS OF RECOMBINANT HUMAN ERYTHROPOETIN ON 
RED CELL TRANSFUSIONS IN NON-LEUKEMIC ADULT AUTOLOGOUS 
STEM CELL TRANSPLANTS: A RETROSPECTIVE EVALUATION 
Paivmm~:, ~ l; Bez,eridge, 3/1.~; Bagshaw, K J; SIJel"idml, 3/1.:; O'rlojf 
G. l I. Failfa.v Ste'm Cell Tra~lspl~rl~t Program INOI,~4 I"aiJfzx Hospital 
Ca'mer CeJete'J; Faaflx, I'~t; 2. INOb~t Fai*fll:c Hospital, PaiJfmv, ~'~4. 
Recombinant Human Erythropoetin (rHu-Epo) reduces the 
number of Red Blood Cell (RBC)transfusions and improves per- 
formance status in patients receiving myelosuppressive 
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SUDDEN BILATERAL VISUAL LOSS DUE TO DISSEMINATED FUSARIO- 
SIS DIAGNOSED BY CULTURE AND POLYMERASE CHAIN REACTION 
l'~lsUtes, J.A.; BelT-Josep,~, A.M.; ShTgb, S.; Chal~dl"asekar, P.H.; 
Abracns, G.H,(; P/am; 0.; RezaeL K Detroit ~ledi~vd CeT~tev-I,~zyTle 
State Uldz~e/sit 3, School of 34ediei1~e, Detroit,, 3/11. 
Invasive fungal infections (IFI) have become a major cause of 
morbidity and mortality in the bone marrow transplant popula- 
tion. One of the greatest challenges in these patients i  to make an 
early diagnosis of an [FI. We describe a patient with ANIL who 
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